Net profit of Aurobindo Pharma rose 7.95% to Rs 817.38 crore in the quarter ended September 2024 as against Rs 757.18 crore during the previous quarter ended September 2023. Sales rose 6.93% to Rs 7646.21 crore in the quarter ended September 2024 as against Rs 7150.71 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales7646.217150.71 7 OPM %20.4819.21 - PBDT1589.741493.14 6 PBT1207.461075.64 12 NP817.38757.18 8 Powered by Capital Market - Live News

Aurobindo Pharma will hold a meeting of the Board of Directors of the Company on 9 November 2024Powered by Capital Market - Live News

Aurobindo Pharma has completed the acquisition of balance 49% stake in its subsidiary, GLS Pharma on 25 October 2024. With this transaction, GLS Pharma has become a wholly owned subsidiary of the Company.Powered by Capital Market - Live News

Aurogen South Africa (Aurogen), a wholly owned step-down subsidiary of Aurobindo Pharma in South Africa, has entered into an agreement with Novabee Proprietary, to sell and dispose of the entire 50% shares held by Aurogen in Novagen. After the disposal of 50% shares held by Aurogen, Aurogen will cease to be the joint venture partner of Novagen.Powered by Capital Market - Live News

Aurogen South Africa, (Aurogen) a wholly owned step-down subsidiary of Aurobindo Pharma in South Africa, has entered into an agreement with Rene Glyne Family trust to sell and dispose of the entire 24.5% shares held by Aurogen. After the disposal of 24.5% shares held by Aurogen, Aurogen will cease to be the joint venture partner of Novagen BBBEE Invest Co (Proprietary). Powered by Capital Market - Live News